The performance was below anticipated levels, primarily due to external factors such as seasonal disruption that affected overall results
The Board of Directors of the company recommends a final dividend of Rs. 42 per equity share for the 12 months period ended March 31, 2025
The Pediatric vaccine portfolio delivered double-digit growth and maintained its market leadership in the private market
Strong topline growth driven by solid performance across key brands.
The company is committed to a new category development in areas like adult Immunization with products like Shingrix to make a positive impact to the lives of the patients in India
General Medicine grows 5% and Vaccines 10% led by Shingrix
QS-21 in blockbuster Shingles vaccine, first vaccine approved for Malaria, promising RSV phase III candidate, and Covid-19 applications.
Subscribe To Our Newsletter & Stay Updated
